Literature DB >> 15949930

Determination of intracellular cytokines produced by Th1 and Th2 cells using flow cytometry in patients with brucellosis.

H Handan Akbulut1, S Sirri Kilic, Vedat Bulut, Mehmet Ozden.   

Abstract

The aim of the study was to evaluate intracellular interferon-gamma (IFN-gamma), and interleukin-4 (IL-4) levels in pre- and post-treatment periods of brucellosis patients and to determine the relationship between these parameters and patients' clinical findings. Twenty-five patients diagnosed as brucellosis and 11 aged-matched healthy volunteers were included in the study. CD3+CD4+ T lymphocytes levels were significantly lower in patients with brucellosis as compared to the control group. CD3+CD8+ T lymphocytes and CD3+IFN-gamma+ levels were increased in brucellosis patients compared with the control group. CD4+IFN-gamma+ and CD4+IL-4+ levels were no different between patients and healthy individuals. CD3+IL-4+ levels decreased in patients compared with healthy controls. Pre-treatment CD3+IFN-gamma+ levels dramatically increased in patients responsive to management compared with the unresponsive ones. In responsive cases, CD3+IFN-gamma+ levels decreased statistically after the treatment while in unresponsive cases no meaningful change was observed with respect to treatment. Adding IFN-gamma to the treatment for improving the depleted levels of IFN-gamma can be beneficial in patients with brucellosis who shows a tendency to chronicity or patients who do not respond to the treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15949930     DOI: 10.1016/j.femsim.2005.04.001

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  7 in total

1.  Human brucellosis is characterized by an intense Th1 profile associated with a defective monocyte function.

Authors:  Manuel Rodríguez-Zapata; Marlene J Matías; Alfredo Prieto; Marco A Jonde; Jorge Monserrat; Lorenzo Sánchez; Eduardo Reyes; Antonio De la Hera; Melchor Alvarez-Mon
Journal:  Infect Immun       Date:  2010-04-19       Impact factor: 3.441

2.  Key immunity characteristics of diverse stages of brucellosis in rural population from Inner Mongolia, China.

Authors:  Yongzhang Zhu; Li Shi; Yige Zeng; Dongri Piao; Yingbo Xie; Juan Du; Meng Gao; Wei Gao; Junli Tian; Jun Yue; Min Li; XiaoKui Guo; Yufeng Yao; YaoXia Kang
Journal:  Infect Dis Poverty       Date:  2022-06-04       Impact factor: 10.485

3.  Brucella melitensis T cell epitope recognition in humans with brucellosis in Peru.

Authors:  Anthony P Cannella; Cecilia S Lindestam Arlehamn; John Sidney; Kailash P Patra; Katherine Torres; Renee M Tsolis; Li Liang; Philip L Felgner; Mayuko Saito; Eduardo Gotuzzo; Robert H Gilman; Alessandro Sette; Joseph M Vinetz
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

Review 4.  Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.

Authors:  Rongjiong Zheng; Songsong Xie; Shaniya Niyazi; Xiaobo Lu; Lihua Sun; Yan Zhou; Yuexin Zhang; Kai Wang
Journal:  J Immunol Res       Date:  2018-05-17       Impact factor: 4.818

5.  Comparison of the serum level of interleukin-4 in patients with brucellosis and healthy controls.

Authors:  Peyman Eini; Mohammad Mahdi Majzoobi; Hamid Reza Ghasemi Basir; Zahra Moosavi; Abbas Moradi
Journal:  J Clin Lab Anal       Date:  2020-02-26       Impact factor: 2.352

6.  Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development.

Authors:  Anthony P Cannella; Renee M Tsolis; Li Liang; Philip L Felgner; Mayuko Saito; Alessandro Sette; Eduardo Gotuzzo; Joseph M Vinetz
Journal:  Front Cell Infect Microbiol       Date:  2012-02-01       Impact factor: 5.293

7.  Importance of EMT Factor ZEB1 in cDC1 "MutuDC Line" Mediated Induction of Th1 Immune Response.

Authors:  Shuchi Smita; Abdul Ahad; Arup Ghosh; Viplov K Biswas; Marianna M Koga; Bhawna Gupta; Hans Acha-Orbea; Sunil K Raghav
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.